Dash Bio Raises $30M in Series A Funding to Develop Automated Bioanalysis Platform for Drug Discovery

Source: AI Insider·2026-08-04 19:46Publish time unverified

Insider Brief Dash Bio has raised $30 million in Series A funding to expand its automated bioanalysis laboratory and software platform, bringing its total capital raised to $47.5 million. Oak HC/FT led the round, with participation from existing investors Freestyle Capital and Swift Ventures.